Many countries use trivalent measles-mumps-rubella (MMR) vaccine for
their mumps and rubella immunization programs.
In Finland, a national 2-dose MMR vaccination program for children,
free of charge and on a voluntary basis, was launched in 1982. Serological
confirmation of all suspected cases of mumps and rubella has been required
since 1987. Despite intensive surveillance, no persistent sequelae or deaths
attributable to vaccination have been detected. Indigenous mumps and rubella
were eliminated in 1996, but 4 imported cases of mumps and 2 of rubella occurred
from 1997 to 1999. Lack of secondary cases indicates sufficient immunity in
the community. Compared with an epidemic year, up to thousands of cases of
mumps meningoencephalitis and orchitis and around 50 cases of congenital rubella
syndrome are now avoided annually.
A 2-dose vaccine regimen in children during the last 17 years (1983-1999)
has interrupted circulation of the target viruses entirely. Finland is the
first country documented to be free of indigenous mumps and rubella (measles
was eliminated in 1996). Despite the ongoing possibility of imported disease,
major outbreaks probably can be avoided by maintaining high vaccination coverage
and the 2-dose policy.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 61
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.